Latest Breaking News On - Maintenance treatment - Page 31 : comparemela.com

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJun saitoMegan ostrowerMarcelo freireJohn cunninghamSimon travisFachinformation entyvioTakeda pharmaceutical company limitedKennedy instituteEuropean unionInternational mediaGlobal medical affairsExchange commissionUniversity of oxfordTakeda pharmaceutical companyNew england journal

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus. | March 30, 2023

United statesSimon travisJohn cunninghamFachinformation entyvioMarcelo freireExchange commissionGlobal medical affairsEuropean unionKennedy instituteUniversity of oxfordTakeda pharmaceutical company limitedNew england journalProfessor simon travisTranslational gastroenterology unitVice presidentTherapeutic area head

AbbVie to Present Data from Extensive Portfolio at American College of Gastroenterology Annual Scientific Meeting

Data illustrates AbbVie s commitment to providing research and innovative solutions that support patients with high disease burden and unmet needOral presentations address treatment of moderate to severe Crohn s disease, including

United statesPuerto ricoCeline goldbergerBoehringer ingelheimIronwood pharmaceuticalsAllergan united states incAmerican college of gastroenterologyExchange commissionLaboratory values as proxies for endoscopicAbbvie incUs medical affairsAmerican collegeAnnual scientific meetingScientific meetingEndoscopic improvementsRisankizumab induction

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Pati

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with AripiprazoleOtsuka Pharmaceutical Europe Ltd. (“Otsuka”) and H. Lundbeck A/S (“Lundbeck”) today announce that the European.

United statesOtsuka europeThomas mikkel mortensenAlison rossAbilify maintenaOtsuka united kingdom pharma europe ltdOtsuka pharmaceutical company ltdWorld health organisationOtsuka pharmaceutical europe ltdEuropean medicines agencyEuropean medicines agency commencesMedia relations lead corpOtsuka holdings co ltdEuropean medicines agency commences reviewMonth long acting injectableMaintenance treatment

Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 Congress

Gilead and Kite Oncology to present latest blood cancer research at the European Hematology Association (EHA) 2022 CongressSub-analyses from Kite’s ZUMA-7 study of CAR T cell therapy in second-line diffuse large B cell lymphoma includes data in patients over 65 and by tumour burden characteristicsLonger-term d.

United statesDavid sallmanArmin ghobadiKrish patelPatrickm reaganNatalia garcia martinBrexucabtagene autoleucel brexuJason westinAxicabtagene ciloleucelNishanthan rajakumaraswamyMichaelj zorattiDick sundhJamesy chenCressida robsonBrexucabtagene autoleucelCarlo visco